Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 221

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview 8
Therapeutics Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development 9
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area 10
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication 11
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies 18
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes 34
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment 36
Assessment by Monotherapy/Combination Products 36
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development 43
Aduro BioTech, Inc. 43
Agenus, Inc. 44
Aurigene Discovery Technologies Limited 45
BeiGene, Ltd. 46
Beijing Hanmi Pharmaceutical Co., Ltd. 47
BIOCAD 48
Cellular Biomedicine Group, Inc. 49
CytomX Therapeutics, Inc. 50
Eli Lilly and Company 51
Enumeral Biomedical Holdings, Inc. 52
Immunovo BV 53
Jiangsu Hengrui Medicine Co., Ltd. 54
Jounce Therapeutics, Inc. 55
Les Laboratoires Servier SAS 56
MacroGenics, Inc. 57
MD Biosciences GmbH 58
MedImmune, LLC 59
Merck & Co., Inc. 60
Molecular Partners AG 62
Novartis AG 63
Ono Pharmaceutical Co., Ltd. 64
Pfizer Inc. 68
PharmaEssentia Corporation 69
Pieris Pharmaceuticals Inc 70
Regeneron Pharmaceuticals Inc 71
Sutro Biopharma, Inc. 72
Symphogen A/S 73
Tasly Pharmaceutical Group Co., Ltd. 74
Tesaro, Inc. 75
Theravectys SA 76
Tikcro Technologies, Ltd. 77
Vyriad 78
Xencor, Inc. 79
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles 80
AM-0001 - Drug Profile 80
AMP-224 - Drug Profile 81
Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile 83
AUR-012 - Drug Profile 84
BGB-108 - Drug Profile 85
BGBA-317 - Drug Profile 86
Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 87
Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile 88
durvalumab + MEDI-0680 - Drug Profile 89
ENUM-003 - Drug Profile 90
ENUM-388D4 - Drug Profile 92
GXP-2 - Drug Profile 93
IBI-308 - Drug Profile 94
JS-001 - Drug Profile 95
MD-402 - Drug Profile 96
mDX-400 - Drug Profile 97
MEDI-0680 - Drug Profile 98
MGD-013 - Drug Profile 99
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 100
Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 101
Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 102
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 103
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 104
Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile 105
Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile 106
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 107
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 108
Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 109
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 110
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 111
Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 112
Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile 113
Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile 114
Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile 115
Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile 116
Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile 117
nivolumab - Drug Profile 118
Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile 148
pazopanib hydrochloride + pembrolizumab - Drug Profile 149
PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile 150
PDR-001 - Drug Profile 151
PEGMP-7 - Drug Profile 152
pembrolizumab - Drug Profile 153
PF-06801591 - Drug Profile 185
PRS-332 - Drug Profile 186
Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile 187
REGN-2810 - Drug Profile 188
SHR-1210 - Drug Profile 190
SNPD-07 - Drug Profile 191
STIA-1110 - Drug Profile 192
TSR-042 - Drug Profile 193
Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 194
Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 195
Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 196
XmAb-20717 - Drug Profile 197
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects 198
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products 199
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases 200
Appendix 216
Methodology 216
Coverage 216
Secondary Research 216
Primary Research 216
Expert Panel Validation 216
Contact Us 216
Disclaimer 217

List of Tables

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Comparative Analysis by Unknown Stage Development, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 24
Products under Development by Companies, H2 2016 (Contd..1) 25
Products under Development by Companies, H2 2016 (Contd..2) 26
Products under Development by Companies, H2 2016 (Contd..3) 27
Products under Development by Companies, H2 2016 (Contd..4) 28
Products under Development by Companies, H2 2016 (Contd..5) 29
Products under Development by Companies, H2 2016 (Contd..6) 30
Products under Development by Companies, H2 2016 (Contd..7) 31
Products under Development by Companies, H2 2016 (Contd..8) 32
Products under Development by Companies, H2 2016 (Contd..9) 33
Products under Development by Companies, H2 2016 (Contd..10) 34
Products under Development by Companies, H2 2016 (Contd..11) 35
Products under Development by Companies, H2 2016 (Contd..12) 36
Products under Development by Companies, H2 2016 (Contd..13) 37
Number of Products under Investigation by Universities/Institutes, H2 2016 38
Products under Investigation by Universities/Institutes, H2 2016 39
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 44
Number of Products by Stage and Molecule Type, H2 2016 46
Pipeline by Aduro BioTech, Inc., H2 2016 47
Pipeline by Agenus, Inc., H2 2016 48
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 49
Pipeline by BeiGene, Ltd., H2 2016 50
Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 51
Pipeline by BIOCAD, H2 2016 52
Pipeline by Cellular Biomedicine Group, Inc., H2 2016 53
Pipeline by CytomX Therapeutics, Inc., H2 2016 54
Pipeline by Eli Lilly and Company, H2 2016 55
Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 56
Pipeline by Immunovo BV, H2 2016 57
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 58
Pipeline by Jounce Therapeutics, Inc., H2 2016 59
Pipeline by Les Laboratoires Servier SAS, H2 2016 60
Pipeline by MacroGenics, Inc., H2 2016 61
Pipeline by MD Biosciences GmbH, H2 2016 62
Pipeline by MedImmune, LLC, H2 2016 63
Pipeline by Merck & Co., Inc., H2 2016 64
Pipeline by Molecular Partners AG, H2 2016 66
Pipeline by Novartis AG, H2 2016 67
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 68
Pipeline by Pfizer Inc., H2 2016 72
Pipeline by PharmaEssentia Corporation, H2 2016 73
Pipeline by Pieris Pharmaceuticals Inc, H2 2016 74
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 75
Pipeline by Sutro Biopharma, Inc., H2 2016 76
Pipeline by Symphogen A/S, H2 2016 77
Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 78
Pipeline by Tesaro, Inc., H2 2016 79
Pipeline by Theravectys SA, H2 2016 80
Pipeline by Tikcro Technologies, Ltd., H2 2016 81
Pipeline by Vyriad, H2 2016 82
Pipeline by Xencor, Inc., H2 2016 83
Dormant Projects, H2 2016 202
Discontinued Products, H2 2016 203

List of Figures

Number of Products under Development for, H2 2016 13
Number of Products under Development by Therapy Area, H2 2016 14
Number of Products under Development by Indication, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Early Stage Products, H2 2016 20
Assessment by Monotherapy/Combination Products, H2 2016 40
Number of Products by Mechanism of Actions, H2 2016 41
Number of Products by Stage and Mechanism of Actions, H2 2016 41
Number of Products by Routes of Administration, H2 2016 43
Number of Products by Stage and Routes of Administration, H2 2016 43
Number of Products by Molecule Types, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 45
  • United States Gene Synthesis Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 27-Jun-2017        Price: US 4480 Onwards        Pages: 117
    Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. ......
  • Global Biopreservation Market Research Report 2017
    Published: 27-Jun-2017        Price: US 2900 Onwards        Pages: 108
    In this report, the global Biopreservation market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Biopreservation in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Jap......
  • EMEA (Europe, Middle East and Africa) Laser Capture Microdissection Market Report 2017
    Published: 23-Jun-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the EMEA Laser Capture Microdissection market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Laser Capture Microdissection for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia......
  • Europe Cytokines Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 22-Jun-2017        Price: US 4480 Onwards        Pages: 124
    Cytokines are a large group of small signaling molecules that function extensively in cellular communication. Cytokines are most often associated with various immune modulating molecules that include interleukins, chemokines, and interferons, but can also include other molecules as well. Their use in disease diagnosis and treatment has proven very beneficial over the past number of years as their use as biomarkers has been adopted as a means to understanding disease and therapies. They have expa......
  • Global Phloem Fibre Market Professional Survey Report 2017
    Published: 22-Jun-2017        Price: US 3500 Onwards        Pages: 104
    This report studies Phloem Fibre in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Camira Fabrics - FlexForm Technologies - Bast Fibers LLC - American Hem......
  • North America Ion Indicators Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Jun-2017        Price: US 4480 Onwards        Pages: 118
    This report studies the Ion Indicators market. Ion indicators include mental indicators, PH indicators and so on. Scope of the Report: This report focuses on the Ion Indicators in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application. Market Segment by Manufacturers, this report covers - Thermo Fisher Scientific - ATT - Abcam ......
  • Global Microbial Growth Media Market 2017-2021
    Published: 21-Jun-2017        Price: US 3500 Onwards        Pages: 71
    Growth media is of great importance for microbiological tests; it helps obtain pure cultures, grow and count microbial cells, and cultivate and select microorganisms. High-quality growth media is important to achieve accurate and reproducible results of microbiological tests. The microbial growth medium encourages the growth of microorganisms. Microbial growth media contains nutrients, growth promoting factors, energy sources, buffer salts, minerals, metals, and gelling agents. It has been us......
  • Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 54
    Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H1 2017 Summary Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by......
  • Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017
    Published: 20-Jun-2017        Price: US 3500 Onwards        Pages: 34
    Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017 Summary Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ring structure at the future cell division site. The regulation of the ring assembly controls the timing and the location of cell division. It recruits other cell division proteins to the septum to produce a new cell wall between the dividing cells. It binds......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs